Argenx SE (ARGX) shares plummeted 13.54% in pre-market trading on Thursday, following the release of its first-quarter earnings report. The significant drop comes despite the company reporting better-than-expected earnings per share, highlighting investors' concerns about other aspects of the financial results.
The biopharmaceutical company reported Q1 earnings of $2.58 per diluted share, surpassing analysts' expectations of $2.41 and marking a substantial improvement from the $1.04 loss per share in the same quarter last year. However, operating income for the quarter ended March 31 rose to $807.4 million, up from $412.5 million in the previous year, falling short of the $817.6 million forecast by analysts surveyed by FactSet.
Adding to investor uncertainty, Argenx maintained its financial guidance for the fiscal year 2025, targeting combined selling, general and administrative (SG&A) and research and development (R&D) expenses of approximately $2.5 billion. The unchanged guidance, coupled with the lower-than-expected operating income, appears to have overshadowed the positive EPS surprise, leading to the sharp pre-market decline in Argenx's stock price. As the trading day progresses, market watchers will be keen to see if Argenx can recover from this pre-market plunge and address concerns about its future growth prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.